Key result
Aortic stenosis is linked to ~92% higher major cardiovascular events risk in chronic hemodialysis patients.
Why the study?
Valvular heart disease is prevalent and linked to adverse cardiovascular outcomes in patients with ESKD undergoing hemodialysis, but data remain limited regarding the prognostic impact across different VHD subtypes in this population.
Does the presence of specific valvular heart disease subtypes increase the risk of all-cause mortality, major adverse cardiovascular events (MACE), and cardiovascular mortality in chronic hemodialysis patients?
Cohort (n=238)
No
Does the presence of specific valvular heart disease subtypes increase the risk of all-cause mortality, major adverse cardiovascular events (MACE), and cardiovascular mortality in chronic hemodialysis patients?
In chronic hemodialysis patients, specific valvular lesions like aortic stenosis and mitral regurgitation are linked to increased MACE and all-cause mortality, highlighting the importance of VHD subtype evaluation for risk stratification.
Answers are grounded in this paper and cite their sources.
May support lesion-specific risk assessment in hemodialysis; hypothesis-generating for targeted interventions.
Valvular heart disease (VHD) is highly prevalent in patients with end-stage kidney disease (ESKD) undergoing hemodialysis (HD), and is linked to adverse cardiovascular outcomes. However, data remain limited regarding its prognosis impact across different types of VHD in the population. We conducted a retrospective cohort study of 238 chronic HD patients with echocardiographic assessments at a single medical center. VHD was identified and classified by lesion types and number of affected valves (isolated vs. multivalvular). Clinical outcomes included all-cause mortality, major adverse cardiovascular events (MACE), and cardiovascular mortality. Cox proportional hazards models and Kaplan-Meier analyses were used for analysis. VHD was present in 87.4% of the cohort, with mitral regurgitation (MR) being the most common (91.3%), followed by aortic regurgitation (48.6%), aortic stenosis (13.0%), and mitral stenosis (1.4%). VHD patients were older and had higher coronary artery disease prevalence. Although VHD presence was not significantly associated with adverse outcomes in multivariable models, Kaplan-Meier analysis showed higher event trends (MACE: 38% vs. 20%; CV mortality: 18.3% vs. 6.7%). Subgroup analysis revealed that aortic stenosis (AS) was significantly associated with increased MACE risk (adjusted HR: 1.919; 95% CI: 1.065–3.548), and exploratory analyses suggested MR might be associated with all-cause mortality (adjusted HR: 2.538; 95% CI: 1.000–6.446). While overall VHD presence was not independently predictive of adverse outcomes, exploratory analyses identified potential associations between specific valvular lesions, such as AS and MR, and adverse clinical outcomes, emphasizing the need for further VHD subtype evaluation and risk stratification in chronic HD population.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2026) conducted a cohort in End-stage kidney disease on chronic hemodialysis with valvular heart disease (n=238). Valvular heart disease (specifically aortic stenosis and mitral regurgitation subtypes) vs. Absence of valvular heart disease (or specific lesion subtype) was evaluated on Major adverse cardiovascular events (MACE) (HR 1.919, 95% CI 1.065-3.548). Aortic stenosis increased major cardiovascular events risk in chronic hemodialysis patients, though overall VHD was not independently predictive.
Synapse has enriched 10 related papers. Consider them for comparative context: